1. Considered and approved the standalone audited financial results of the company for the quarter and financial year ended 31st March 2026; 2. Considered and approved the appointment ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genomic Valley Biotech Ltd's board approved the standalone audited financial results for Q4 and FY ended March 31, 2026. The company posted a net loss of Rs. 8,34,895 compared to a net profit of Rs. 3,03,041 in the previous year — a sharp swing from profit to loss. Revenue from operations stood at Rs. 26.35 lakhs. Total assets as of March 31, 2026 were Rs. 4.24 crore. The board also appointed Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2026-27. Statutory auditors Andros & Co. issued an unmodified (clean) opinion on the financial statements.
The company swung from a profit of Rs. 3.03 lakh to a loss of Rs. 8.35 lakh in one year — a significant deterioration that shareholders will watch closely. The clean audit opinion and positive operating cashflow of Rs. 4.52 lakh provide some comfort despite the loss.